J Stroke Search

CLOSE


J Stroke > Volume 28(3); 2026 > Article
Li, Sun, Wang, Zhang, and Cheng: Genetic Insights Into Cryptogenic Stroke: From Etiologic Heterogeneity to Clinical Translation

Abstract

Cryptogenic stroke remains challenging because its complex etiology and limited diagnostic tools hinder precise secondary prevention. Growing genetic evidence suggests that cryptogenic stroke may have identifiable genetic architectures that provide additional insights into etiologic classification. In recent years, large-scale genome-wide association studies, multi-omics integration, and other genetic investigations have begun to reveal signals linked to several potential causes, including occult atrial fibrillation and atrial cardiopathy, nonstenotic carotid artery plaque, patent foramen ovale-related paradoxical embolism, monogenic disorders, clonal hematopoiesis of indeterminate potential, and cancer-related thrombosis. These findings suggest a possible shift from exclusion-based diagnosis toward a more mechanism-driven approach. Recent genetic discoveries have enabled preliminary work on predictive models for risk stratification. Emerging genetic tools may also offer promising approaches for etiologic stratification and mechanistic investigation. However, current research in this area remains limited by heterogeneous definitions, modest sample sizes, limited ancestral diversity, and gaps in mechanistic and prognostic evidence. Consequently, clinical translation remains at an early stage. Future research should establish larger and more diverse genomic cohorts with longitudinal phenotyping and advance multidimensional data integration. These efforts may refine etiologic classification and support precision treatment in cryptogenic stroke.

Introduction

Stroke is the second leading cause of death worldwide and the third leading cause of combined death and disability [1]. Identifying the underlying cause is essential for guiding secondary prevention after stroke [2,3]. Even after a comprehensive diagnostic evaluation, approximately 30%-40% of ischemic strokes remain unexplained and are therefore classified as cryptogenic [3,4]. Rather than representing a single disease entity, cryptogenic stroke is a clinically heterogeneous category encompassing diverse, often occult etiologies [5,6]. This persistent etiologic uncertainty limits the ability to optimize secondary prevention and underscores the need to better define the biological mechanisms of cryptogenic stroke.
As efforts to better characterize the etiologic heterogeneity of cryptogenic stroke have evolved, the concept of embolic stroke of undetermined source (ESUS) was introduced as a clinical construct for patients without lacunar infarction, major-risk cardioembolic sources, significant arterial stenosis, or other specific causes [7]. Although ESUS provides a standardized framework for patient selection, it represents a clinically defined subgroup within the broader spectrum of cryptogenic stroke. The concept is based on the assumption that these strokes may have an underlying embolic mechanism despite the absence of an identified embolic source [7]. However, several major randomized trials have not demonstrated an overall benefit of anticoagulation over aspirin in their respective study populations. These include NAVIGATE ESUS (New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source) [8], RE-SPECT ESUS (Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate versus Acetylsalicylic Acid in Patients with Embolic Stroke of Undetermined Source) [9], ATTICUS (Apixaban for Treatment of Embolic Stroke of Undetermined Source) [10], and ARCADIA (Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke) [11]. These findings highlight the limitations of current clinical phenotyping and emphasize the need for additional approaches to refine etiologic characterization and patient stratification.
Against this background, genetic studies are becoming an increasingly valuable complement to conventional clinical evaluation, providing biological insights that may not be captured by routine phenotypic assessment. In recent years, multiple genomic and multi-omics approaches, including genome-wide association studies (GWAS), polygenic risk scores (PRS), RNA sequencing and proteomic profiling, have provided new insights into several potential causes of cryptogenic stroke and suggested possible diagnostic relevance [12-14]. However, existing reviews have either focused on individual potential etiologies of cryptogenic stroke in isolation or addressed multiple potential etiologies primarily from a clinical perspective, without systematically integrating genetic evidence. As a result, the contribution of genetic variation to etiologic heterogeneity, the current clinical relevance of genetic evidence, and its future translational potential in cryptogenic stroke remain incompletely understood.
To provide a more comprehensive understanding of cryptogenic stroke, this review synthesizes current genetic evidence across major potential etiologies of cryptogenic stroke. We aim to summarize how genetic architecture may relate to underlying mechanisms and explore how genetic insights may inform future etiologic stratification and clinical research. Figure 1 illustrates the potential etiologies discussed in this review and reflects the potential value of genetic research in cryptogenic stroke. In addition, we discuss current challenges and future directions regarding the potential role of genetic insights in precision medicine for cryptogenic stroke.

Genetic insights into the etiologic heterogeneity of cryptogenic stroke

Genetic studies have provided supportive evidence for several major potential etiologies. The following sections review the current genetic evidence for each major etiologic category.

Cardioembolic etiologies

Atrial fibrillation

Subclinical atrial fibrillation (AF) is an important potential cause of cryptogenic stroke. This recognition is supported by evidence from the EMBRACE (30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation After a Cerebral Ischemic Event) and CRYSTAL AF (Cryptogenic Stroke and Underlying Atrial Fibrillation) trials, which demonstrated that prolonged cardiac monitoring substantially increases AF detection after cryptogenic stroke [15,16]. Meanwhile, empirical anticoagulation in patients with ESUS was evaluated in NAVIGATE ESUS and RE-SPECT ESUS. Neither trial demonstrated an overall benefit of anticoagulation over aspirin (Figure 1) [8,9]. Therefore, identifying the subgroup of patients with cryptogenic stroke in whom AF is causally relevant has become a major research focus. Although prolonged rhythm monitoring increases AF detection compared with routine short-term monitoring, its clinical applicability remains limited by cost and adherence [16,17]. In addition, existing prediction scores based on clinical and imaging parameters have limited ability to identify individuals at high risk of occult AF [18]. This diagnostic gap has prompted growing interest in the genetic features of AF as a potential complementary approach.
Since the first GWAS of AF (Figure 1) [19,20], studies based on large biobanks have progressively outlined its complex genetic architecture [21,22]. A large GWAS meta-analysis identified more than 350 loci associated with AF, highlighting its highly polygenic basis [14]. These risk loci implicate biological processes related to myocardial structure and function, cardiac development, and ion channel activity [14]. Genetic variants representing these distinct mechanistic pathways, including variants near PITX2, HCN4, and MYH6, have been associated with different cardiac phenotypes and varying risks of cardioembolic stroke [23]. Furthermore, genetic liability to AF has been associated with stroke of undetermined source, although the strength of this association varies according to diagnostic completeness and classification criteria [24,25]. Together, these findings provide genetic evidence for the potential contribution of AF to cryptogenic stroke.
The growing understanding of AF genetics has also prompted increasing interest in its potential diagnostic utility in stroke populations. AF PRSs have shown potential for identifying patients at increased risk of AF after stroke, as well as for discriminating between cardioembolic and non-cardioembolic stroke [26,27]. Their performance may be further improved when combined with clinical risk factors [26,27]. However, AF-related PRS has not been well studied in cryptogenic stroke populations, and its predictive value in this setting remains to be established.

Atrial cardiopathy

Beyond AF itself, atrial structural abnormalities have been proposed to create a thrombogenic substrate through impaired atrial function, blood stasis, endothelial dysfunction, and inflammation, thereby promoting thromboembolism [28]. The concept of atrial cardiomyopathy was therefore introduced [29]. Clinically, several markers of atrial cardiopathy, including structural, electrical, and functional abnormalities, have been associated with ischemic stroke or cardioembolic stroke [30,31]. However, their clinical utility for identifying patients in whom atrial cardiopathy may be etiologically relevant remains uncertain [31]. This uncertainty is particularly relevant because the presence of atrial cardiopathy may also have therapeutic implications, especially regarding the selection of patients for anticoagulation. In a secondary analysis of the NAVIGATE ESUS trial, neither HAVOC (hypertension, age, valvular heart disease, peripheral vascular disease, obesity, congestive heart failure, and coronary artery disease) score tertiles nor premature atrial contraction burden modified the effect of rivaroxaban on recurrent ischemic stroke [32]. In contrast, patients with marked left atrial enlargement (left atrial diameter >4.6 cm) appeared to derive greater benefit from rivaroxaban, suggesting that left atrial structural abnormalities may help identify a subgroup of ESUS patients who potentially benefit from anticoagulation [32]. However, subsequent randomized trials evaluating different patient selection strategies yielded neutral results. The ATTICUS trial enrolled a broader ESUS population enriched for cardioembolic risk using clinical, electrocardiographic, or echocardiographic predictors, whereas the ARCADIA trial adopted a more targeted strategy by specifically enrolling patients with atrial cardiopathy but without AF. Neither trial demonstrated the superiority of apixaban over aspirin for secondary stroke prevention (Figure 1) [10,11]. Collectively, these findings suggest that atrial cardiopathy may contribute to stroke risk in a subset of patients with cryptogenic stroke, highlighting the need for improved phenotyping and risk stratification and for further studies to determine the implications for secondary prevention.
Genetic studies specifically investigating atrial cardiopathy remain scarce, with even fewer focusing on cryptogenic stroke. A large-scale, systematic Mendelian randomization study evaluated 66 cardiac traits and investigated their potential causal associations with ischemic stroke and its subtypes, including cryptogenic stroke [24]. The evaluated cardiac traits encompassed electrocardiographic measures, cardiac imaging traits, and circulating biomarkers, including P-wave terminal force in V1 and N-terminal pro-B-type natriuretic peptide, two commonly used markers of atrial cardiopathy. The results showed that, aside from AF and coronary artery disease, there was little evidence supporting independent associations between other cardiac traits, including atrial cardiopathy-related biomarkers, and stroke of undetermined causes as defined by the Causative Classification of Stroke System (CCS) [24]. Building on recent advances in imaging genetics, a subsequent study constructed polygenic scores for multiple measures of left atrial structure and function using GWAS data and evaluated their associations with incident ischemic stroke [33]. When considering AF as a competing risk, the polygenic score for left atrial passive emptying fraction remained significantly associated with ischemic stroke, suggesting that atrial dysfunction may contribute to stroke risk independently of AF. Mendelian randomization analyses further supported a protective effect of higher left atrial passive emptying fraction on cardioembolic stroke [33]. However, these findings have not yet been specifically validated in patients with cryptogenic stroke [33]. At the level of individual genes, functional studies have identified several genes involved in atrial structural and electrical remodeling, including ETV1 [34], MYL4 [35], CIB2 [36], and PITX2 [37]. However, whether variation in these genes contributes to cryptogenic stroke through atrial cardiopathy-related pathways remains largely unexplored.
Overall, current genetic evidence has not yet established a direct link between atrial cardiopathy and cryptogenic stroke. Further studies may be needed to clarify whether atrial cardiopathy contributes to the pathogenesis of cryptogenic stroke and to define its clinical relevance.

Arterial etiologies

Early imaging studies identified nonstenotic carotid artery plaque (nsCAP) as a potential arterioembolic source in a subset of patients with cryptogenic stroke [38]. nsCAP generally refers to an atherosclerotic carotid plaque producing less than 50% luminal narrowing, which does not meet the conventional stenosis threshold for large-artery atherosclerotic stroke [5]. nsCAPs have been reported in approximately 40% of patients with ESUS, although prevalence estimates vary according to plaque definition, imaging modality, and study population [39,40]. Among patients with unilateral anterior-circulation ESUS, a recent meta-analysis showed that the pooled prevalence of complicated nsCAPs with at least one high-risk feature was 31% ipsilateral and 14% contralateral to the index stroke [41]. This ipsilateral predominance provides further support for a potential etiologic role of nsCAP in cryptogenic stroke [41]. In parallel, imaging studies have increasingly focused on high-risk plaque features beyond the degree of stenosis (Figure 1) [42]. Nevertheless, the causal relationship between an individual nsCAP and the index stroke often remains uncertain [41].
Direct genetic evidence specifically related to nsCAP remains at an early stage. Nevertheless, emerging findings suggest that arterial pathology may contribute to cryptogenic stroke in a subset of patients. A genetic analysis of 16,851 ischemic stroke cases and 32,473 controls from European populations, including up to 4,755 cases of cryptogenic stroke, showed that cryptogenic stroke shares genetic architecture with several other stroke subtypes [25]. Using carotid intima-media thickness (cIMT) as a genetic proxy for carotid atherosclerosis, Mendelian randomization analyses supported an association between genetically predicted carotid atherosclerosis and cryptogenic stroke [25]. Consistent with these findings, at the locus level, a large number of shared loci were observed with large-artery atherosclerotic stroke, with representative genes including ALDH2 and PDE8B [25]. Beyond this genome-wide evidence, additional candidate-gene studies have reported exploratory associations between multiple genetic loci and carotid atherosclerotic phenotypes, including genetic loci implicated in plaque formation (ABCA1 and OLR1) [43,44], plaque vulnerability (BIRC6 and CYP450) [45,46], and cIMT (PDE4D) [47]. However, most of these studies were conducted in small or highly selected populations. These findings should therefore be considered preliminary pending replication in larger, well-phenotyped cohorts and confirmation in genome-wide studies.

Patent foramen ovale and paradoxical embolism

Patent foramen ovale (PFO) has long been recognized as an important potential cause of cryptogenic stroke, primarily through paradoxical embolism [48,49]. However, given the high prevalence of PFO in the general population, distinguishing a causally relevant PFO from an incidental finding remains a major clinical challenge [50]. This challenge prompted a shift toward risk stratification based on anatomical and clinical features such as atrial septal aneurysm [51]. The Risk of Paradoxical Embolism score was subsequently developed using clinical and imaging characteristics, while the PFO-Associated Stroke Causal Likelihood classification further incorporated high-risk PFO features [52,53]. In parallel, early randomized closure trials yielded neutral results [54-56], whereas subsequent evidence from extended follow-up and trials with more refined patient selection demonstrated a reduction in recurrent stroke (Figure 1) [57-59]. These findings further emphasized the importance of identifying patients most likely to benefit from PFO closure.
Genetic evidence may provide additional insights into the biological basis of PFO. Candidate-gene studies have implicated cardiac developmental genes, particularly NKX2-5, in atrial septation abnormalities [60]. In addition, a quantitative trait locus mapping study in mice suggested that PFO susceptibility is influenced by multiple genetic loci affecting atrial septal morphology, indicating a complex genetic basis for PFO [61]. These findings suggest that genetic variation affecting cardiac septation and developmental pathways may contribute to PFO susceptibility; however, their relevance to PFO-associated stroke remains uncertain.
In addition to informing the genetic basis of PFO development, emerging genetic evidence may help explain why stroke occurs in only a subset of individuals with PFO. PFO-related stroke may involve multiple genetic risk factors acting together. One reasonable hypothesis is that individuals with inherited prothrombotic tendencies may be more prone to stroke in the setting of PFO. However, previous case-control studies examining the relationship between inherited thrombophilia and PFO-related stroke were mostly small and yielded inconsistent results [62,63], highlighting the need for larger, well-powered investigations. Furthermore, in a small observational study of patients with ESUS, MTHFR genotypes associated with reduced enzymatic activity were associated with lower L-arginine/asymmetric dimethylarginine (L-Arg/ADMA) ratios and a more severe interatrial septal phenotype [64]. These findings suggest a potential link among MTHFR-related defects, endothelial dysfunction, and interatrial septal abnormalities in cryptogenic stroke. The L-Arg/ADMA ratio has also been proposed as a candidate marker of stroke susceptibility in patients with interatrial septal abnormalities [64]. However, the clinical significance of this proposed mechanism and its causal role in cryptogenic stroke remain uncertain.

Monogenic causes of stroke

Although a growing number of rare monogenic disorders are known to manifest with stroke, they remain potentially overlooked causes of cryptogenic stroke. Their recognition is challenging because of variable penetrance and highly heterogeneous clinical presentations [65]. Stroke may occur either as the predominant manifestation or as part of a broader systemic disorder [66]. Recent systematic sequencing studies in young patients with cryptogenic stroke have identified pathogenic variants consistent with underlying monogenic disorders (Figure 1) [67]. However, genetic testing is not routinely incorporated into the initial diagnostic workup. The etiologic evaluation of cryptogenic stroke currently relies largely on neuroimaging, vascular imaging, cardiac evaluation, and selected hematologic or malignancy-related investigations [68]. Table 1 mainly summarizes representative monogenic disorders identified in sequencing studies of cryptogenic stroke or previously discussed as potential causes of cryptogenic stroke.
Potential monogenic causes deserve greater attention in the etiologic evaluation of cryptogenic stroke. First, monogenic disorders are particularly relevant in young patients because they often present at an early age and may remain unrecognized [67]. Second, several inherited disorders listed in Table 1 have disease-specific management beyond conventional stroke care, including enzyme replacement therapy for Fabry disease [69], vitamin supplementation and metabolic control for homocystinuria [70], and tumor necrosis factor blockade for adenosine deaminase 2 deficiency [71]. Accordingly, recognition of an underlying monogenic disorder may refine etiologic diagnosis, while some diagnoses may also inform disease-specific treatment and secondary prevention.

Potential contributors to cryptogenic stroke

Clonal hematopoiesis of indeterminate potential

Clonal hematopoiesis of indeterminate potential (CHIP) has received increasing attention as a potential contributor to cryptogenic stroke. Before the formal introduction of the CHIP concept, age-related clonal hematopoiesis had already been associated with ischemic stroke [72]. CHIP was subsequently defined as an age-related condition characterized by acquired somatic mutations in hematopoietic stem cells, most commonly involving driver genes such as DNMT3A, TET2, ASXL1, and JAK2, in the absence of overt hematologic malignancy [73,74]. More recent studies further supported the association between CHIP and ischemic stroke, with emerging evidence also linking CHIP to short-term stroke recurrence [75,76]. Associations with both atherosclerosis and AF have also been reported [77,78], further suggesting that the relationship between CHIP and ischemic stroke may be complex (Figure 1).
Although direct evidence linking CHIP to cryptogenic stroke remains limited, the available findings suggest its potential relevance in this population. In a young stroke cohort enriched for cryptogenic stroke, targeted sequencing of CHIP-related genes showed that the prevalence of CHIP was about three times higher than that in the general population. The rate of confirmed myeloid malignancy was nearly twenty times higher [79]. These findings further suggest that CHIP may warrant consideration in selected patients with cryptogenic stroke. Together with previous evidence, the authors raised the possibility that CHIP may contribute to stroke through different biological pathways depending on the specific driver gene involved, although these mechanisms require further investigation [79].

Cancer-associated cryptogenic stroke

Cancer is increasingly recognized as a potential cause of cryptogenic stroke [80,81]. Retrospective studies suggest that a subset of patients with cryptogenic stroke may harbor occult malignancy [82], while cancer is also associated with increased ischemic stroke risk [83]. These findings highlight the importance of identifying occult malignancy in patients with cryptogenic stroke. Subsequent studies have tried to explore risk stratification strategies based on combinations of clinical characteristics, laboratory biomarkers, and imaging features [84]. However, no standardized screening strategy or consensus recommendations have yet been established (Figure 1). To date, genetic and molecular studies specifically addressing occult malignancy in cryptogenic stroke remain scarce. Among the few available studies, one exploratory transcriptomic analysis identified distinct peripheral blood gene expression signatures in patients with both cancer and ischemic stroke compared with those with cancer alone or stroke alone. In addition, a small post hoc analysis showed broadly similar expression profiles between cryptogenic and cardioembolic stroke within the cancer-stroke group [85]. Based on these findings, the authors proposed that gene expression profiling may represent a potential molecular approach for identifying occult malignancy in patients with cryptogenic stroke, although further validation is required [85].

Current value of genetic research in cryptogenic stroke

Advancing mechanistic understanding

Genetic research may provide preliminary insights into the biological mechanisms of cryptogenic stroke. Such findings may help generate mechanistic hypotheses and guide future research. However, current evidence remains limited and largely exploratory. In this context, the role of inflammation has begun to be explored in genetic studies of cryptogenic stroke and is therefore discussed in greater detail below (Figure 2).
Inflammation is involved in the pathogenesis of multiple ischemic stroke etiologies [86-88], as well as in the progression of ischemic brain injury [89]. In the context of cryptogenic stroke, genetic and molecular studies have begun to explore the potential role of inflammation. Early candidate-gene studies reported exploratory associations between variants in genes encoding inflammatory cytokines, including tumor necrosis factor-α and interleukin-10, and cryptogenic stroke [90,91]. More recent Mendelian randomization analyses have provided suggestive evidence that genetically predicted interleukin-6 signaling and C-C motif chemokine ligand 2 levels may be associated with stroke of undetermined source [25]. Together, these findings provide preliminary evidence supporting a potential involvement of inflammatory pathways in cryptogenic stroke, although further mechanistic investigation is needed. Moreover, studies comparing established ischemic stroke subtypes have identified differences in inflammation-related genetic and transcriptomic profiles [92,93]. These differences may provide additional information for etiologic stratification. In particular, transcriptomic signatures have been identified and further explored in patients with cryptogenic stroke [93]. When applied to cryptogenic stroke, gene expression signatures derived from patients with known stroke etiologies classified a subset of patients as potentially cardioembolic or large-vessel stroke, although further validation is required [93].
The mechanisms underlying many potential causes of cryptogenic stroke have primarily been investigated in the corresponding conditions rather than in cryptogenic stroke itself. Against this background, Table 2 summarizes the mechanisms underlying disease development and stroke occurrence across the major potential etiologies of cryptogenic stroke with available genetic evidence. It also outlines how genetic research may contribute to understanding these mechanisms. This summary may help improve our understanding of the biological heterogeneity of cryptogenic stroke and provide directions for future mechanistic studies and more refined etiologic stratification.

Promoting clinical translation

Although accumulating genetic evidence has improved our understanding of the major potential etiologies of cryptogenic stroke, its translation into clinical practice remains limited. Table 3 integrates current clinical evaluation, genetic evidence, and translational perspectives across the major potential etiologies of cryptogenic stroke. Overall, most genetics-based approaches remain at an exploratory stage and should be interpreted cautiously until further clinical validation. The following sections therefore focus on several emerging approaches that may represent potential directions for the clinical translation of genetic and multi-omics information in cryptogenic stroke.

PRS-based etiologic stratification and risk prediction

With increasing GWAS sample size and greater multi-ancestry integration, a growing number of common genetic variants associated with stroke subtypes and their related causes have been identified [94,95]. This progress has encouraged the development of genetically informed prediction models. PRS has become a widely used approach for genetic risk prediction (Figure 2) [96,97]. At present, the primary applications of PRS encompass etiological risk prediction and stroke subtyping, with AF representing one of the most extensively studied applications [26,98]. PRSs for established ischemic stroke subtypes have also been applied to strokes of undetermined source to explore their potential etiologic contributions [25]. While PRS is widely used for genetic risk prediction, several important limitations remain. The predictive performance of conventional PRS models is constrained by the proportion of disease heritability captured by available genetic data [99]. In addition, conventional PRS models are typically based on linear weighting schemes and may fail to capture complex nonlinear interactions among genetic variants [100]. As a result, substantial room remains for improving PRS-based prediction approaches for complex diseases, including cryptogenic stroke [99].
In response, recent research has expanded genetic risk prediction beyond conventional PRS approaches. On the modeling side, methodological innovation offers new opportunities to enhance genetic prediction. One direction is to integrate complementary genetic information from multiple polygenic scores. This may involve combining multiple PRSs for the same trait or extending the combination to genetically related traits [101]. The latter may provide additional predictive gains by leveraging shared genetic architecture and pleiotropy [101]. Component scores are commonly weighted and combined into a composite score, with Elastic Net regression used in several existing frameworks [94,101,102]. In stroke, integrative approaches have combined genetic scores for ischemic stroke and its etiologic subtypes with scores for related traits, including vascular risk factors and comorbidities [94,102]. Such integration has shown improved prediction compared with individual genetic scores [94,102]. Another direction is to explore more flexible genomic modeling approaches beyond conventional PRS frameworks. Machine-learning approaches, including deep learning, may capture nonlinear genetic relationships that are not represented by conventional linear weighting schemes [100,103]. In stroke, this direction has also begun to be explored. For example, the chromosome-wise multi-task genomic framework combines nonlinear modeling with chromosome-level genomic structure and shared genetic information across ischemic stroke and related diseases [100]. In its initial evaluation, this framework showed improved prediction compared with conventional PRS [100]. However, the predictive advantage of nonlinear modeling should be interpreted cautiously, as nonlinear effects may be modest and apparent performance gains may also be influenced by joint tagging effects due to linkage disequilibrium (LD) [104]. On the data side, multidimensional integration provides another direction for improving risk prediction. Genetic information can capture long-term inherited susceptibility, whereas proteomic and metabolomic profiles may provide more dynamic information on physiological processes [105]. Integrating these complementary molecular layers may therefore capture predictive information not represented by genetic risk alone [105]. In ischemic stroke, the sum transcriptome polygenic risk score, which integrates PRS with a transcriptome-based risk score, showed improved discrimination for ischemic stroke and its subtypes compared with PRS alone [106]. Beyond the integration of genetic risk with other molecular data, multi-omics approaches can also combine information across non-genetic molecular layers. In ischemic stroke, the integration of epigenomic and multiple transcriptomic layers has been explored for etiologic classification [107]. Nevertheless, evidence supporting multi-omics approaches in stroke prediction and etiologic classification remains limited. In addition, genetically informed approaches to post-stroke AF prediction have largely combined genetic risk with clinical predictors, whereas brain imaging phenotypes have been less frequently incorporated [27,108]. However, imaging features may provide complementary etiologic information. They have been explored for predicting underlying AF in cryptogenic stroke and identifying potential embolic sources in ESUS [108,109]. Future integration of genetic information with multimodal clinical and imaging data may therefore further support risk stratification and etiologic modeling.
Overall, PRS-based analyses have revealed shared genetic susceptibility between strokes of undetermined source and established ischemic stroke subtypes, but their application to individual-level etiologic stratification remains limited [25]. Flexible genomic modeling and multidimensional data integration approaches have largely been evaluated outside cryptogenic stroke and may inform future prediction studies in this population (Figure 2).

Gene panel-based evaluation for monogenic disorders and CHIP

Gene panel-based testing may provide a targeted approach to complement etiologic evaluation in selected patients with cryptogenic stroke. Potential applications mainly include the identification of overlooked monogenic disorders and somatic CHIP-related mutations. However, the supporting evidence is still limited (Figure 2).
Given the potential for overlooked monogenic causes, both gene panel-based and broader sequencing approaches have been evaluated in young patients with cryptogenic stroke to identify underlying genetic disorders [67,110]. Among young patients with cryptogenic stroke classified according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST), reported diagnostic yields for monogenic disorders ranged from 11.8% to 53.3% [67,110]. These estimates should be interpreted cautiously and require validation in larger cohorts because both studies included small samples of patients with cryptogenic stroke (17 and 30, respectively), and their study designs differed in several aspects [67,110]. Specifically, they differed in age criteria (<50 and <55 years, respectively), study populations (recruited in France and China, respectively), and sequencing approaches (heterogeneous genetic testing or exome sequencing in one study and a uniform 551-gene targeted panel in the other). Molecular diagnosis was also defined differently, as pathogenic or likely pathogenic variants versus pathogenic variants according to the American College of Medical Genetics and Genomics criteria [67,110]. The optimal indications for genetic testing also remain uncertain, and no clear consensus on patient selection has been established [67,110]. Genetic evaluation may be considered after a negative comprehensive etiologic work-up when clinical features suggest an inherited disorder. It may also be considered when clinical or imaging findings suggest conditions with recognized monogenic forms, such as cardiomyopathy, moyamoya angiopathy, or cerebral small vessel disease [67]. A positive family history or familial clustering may further raise suspicion for a monogenic cause [111], but its absence should not preclude genetic evaluation [67].
Beyond inherited monogenic disorders, targeted sequencing has also been explored for the detection of somatic CHIP-related mutations in patients with cryptogenic stroke [79]. However, clinical evidence in cryptogenic stroke remains limited, and the optimal screening strategy has not been established, particularly regarding the target population, gene panel composition, and variant allele frequency (VAF) threshold. For the target population, the available prospective study enrolled patients aged 18-60 years with predominantly cryptogenic stroke [79]. However, given the strong age dependence of CHIP, the value of targeted screening in older patients remains to be determined [74]. In terms of gene panel composition, the study used a 56-gene myeloid panel, with CHIP-associated mutations most frequently detected in DNMT3A, TET2, and ASXL1 [74]. Although CHIP is conventionally defined by VAF ≥2%, the available stroke study used a more sensitive threshold of ≥1% [75,79]. Importantly, CHIP screening may also have implications for subsequent clinical evaluation and management. If high-risk CHIP is identified, further hematologic evaluation for occult myeloid disorders and more intensive management of modifiable vascular risk factors may be considered [79]. The reported association between CHIP and AF may also suggest potential implications for rhythm surveillance, although this application has not been evaluated in cryptogenic stroke [78].
Several challenges currently constrain the further development of genetic testing as a clinically useful tool in cryptogenic stroke. Beyond the modest sample sizes and selected patient populations in the current evidence base [67,79], variant interpretation represents an additional challenge, particularly for monogenic disorders. The detection of a sequence variant alone does not establish a monogenic diagnosis [112]. Specifically, variants should first be classified according to established pathogenicity criteria. Their relevance to the index stroke should then be assessed in the context of the patient’s clinical phenotype, inheritance pattern, and family history [67,112]. Moreover, variants of uncertain significance should not be considered diagnostic in isolation, and additional family segregation or functional studies may be required to clarify their clinical relevance [112]. Finally, although genetic testing may provide additional etiologic diagnoses, evidence for its impact on treatment decisions and clinical outcomes remains limited [67,79]. Overall, further development and validation are still needed before sequencing-based genetic evaluation can be routinely incorporated into clinical practice for cryptogenic stroke.

Thrombus profiling for etiologic inference

Thrombus profiling may provide additional clues to stroke etiology in cryptogenic stroke. In patients with stroke, thrombi caused by different etiologies show differences in composition, which provides a basis for inferring embolic source through clot analysis (Figure 2). Compared with cardioembolic thrombi, those from large-artery atherosclerosis exhibit higher platelet content and a greater proportion of platelet-rich clots [113]. In contrast, cardioembolic thrombi exhibit higher monocyte-to-lymphocyte ratios (MLr) than large-artery atherosclerotic thrombi, along with increased monocyte proportions [114]. Clot MLr was also evaluated in patients with cryptogenic stroke. Higher MLr was associated with the later identification of a high-risk cardioembolic source during extended diagnostic work-up [114]. Together, these findings support the potential use of clot profiling as an additional source of etiologic information in cryptogenic stroke. Transcriptomic profiling may further extend this approach by capturing molecular differences between thrombi of different origins. High-throughput RNA sequencing of thrombi from known carotid and AF sources identified distinct gene expression signatures [13]. Several candidate markers were identified as potential indicators of thrombus origin. However, although the authors also suggested that these gene expression biomarkers may help predict the source of cryptogenic embolism, this application was not directly evaluated in patients with cryptogenic stroke [13]. Moreover, future work combining transcriptomic analysis with histologic assessment and flow cytometry may further improve the clinical value of thrombus profiling in identifying the causes of cryptogenic stroke [13].

Limitations and future directions in genetic research of cryptogenic stroke

As outlined above, genetic studies have provided new insights into the genetic architecture and potential molecular mechanisms of cryptogenic stroke. They may also support etiologic stratification and risk prediction. However, several limitations still constrain their clinical application.
These limitations can be broadly categorized into several key areas (Figure 2). First, the definition of cryptogenic stroke is highly heterogeneous. Differences in classification systems, such as TOAST, CCS, and ESUS, lead to variation in patient inclusion, which directly affects the reproducibility and comparability of genetic association findings [5,7,115]. Second, many existing studies are based on cohorts with limited sample size. These findings require independent validation in larger and multicenter populations. Furthermore, ancestral diversity remains limited in existing genetic studies. Most large genetic studies have been conducted in European populations, while ancestry-related differences in allele frequencies and LD may limit the generalizability of genetic findings [94,95,116]. Beyond these issues, the scope of inference supported by current genetic evidence remains limited at both mechanistic and clinical levels. At the mechanistic level, genetic association studies primarily identify statistical associations between genetic variants and disease traits rather than establish causal genes or biological mechanisms. Functional and experimental studies are therefore often required to clarify their biological relevance [117,118]. At the clinical level, most genetic studies of cryptogenic stroke have focused on incident stroke risk rather than subsequent clinical outcomes. Therefore, the relevance of current genetic findings to secondary prevention in cryptogenic stroke remains uncertain and requires dedicated studies of recurrence and treatment response.
Future research in cryptogenic stroke genetics should focus on several directions (Figure 2). First, genetic approaches may help address the limitations of current cryptogenic stroke classification frameworks and support more refined etiologic subtyping [25]. Integrating genomic data with imaging, biomarkers, and longitudinal phenotyping may further improve the accuracy of this classification. Second, the application of genetic and multi-omics approaches to precision medicine in cryptogenic stroke deserves further attention. On the one hand, genetic approaches may help identify biologically distinct subgroups within cryptogenic stroke [25]. Such stratification may eventually contribute to more individualized clinical management [96,97]. On the other hand, genetic data may support biomarker-guided trial designs by defining patient subgroups that can be matched to specific interventions [119]. Such designs may allow targeted therapies to be evaluated more efficiently in selected patient populations and provide a potential route toward precision treatment [119]. Third, larger and more diverse stroke genomic cohorts are needed to address limitations related to sample size and ancestry imbalance [120,121]. These cohorts would ideally incorporate longitudinal phenotyping after stroke, including recurrence, recovery, and treatment response [121,122]. Several dedicated stroke genetics cohorts have already begun to address these needs across diverse populations. Illustrative examples include the DISCOVERY (Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on Recovery) study in the United States [123], a prospective multicenter cohort focusing on post-stroke cognitive outcomes and recovery; the Formosa Stroke Genetic Consortium in Taiwan [124], a multicenter platform supporting genetic and molecular studies of cerebrovascular disease; the GENESIS-K (GENomic Exploration in Stroke and pharmacogenomic Innovation Study-Korea) cohort [125], a nationwide multicenter prospective stroke cohort supporting population-specific pharmacogenomic research and precision stroke medicine; and the Dutch String-of-Pearls Stroke Study [126], a prospective multicenter genetic cohort with standardized phenotyping. Another important resource is the Stroke Omics Atlas (STROMICS) [127], a multiomics project built upon the Third China National Stroke Registry (CNSR-III) [128], with its Phase I genome study comprising deep whole-genome sequencing of 10,241 Chinese patients alongside detailed phenotyping and longitudinal follow-up. Together, these initiatives broaden the scope of stroke genetics. Future efforts should harmonize post-stroke phenotyping across cohorts. Such harmonization could support future studies of genetic determinants of recurrence and treatment response and provide insights into the potential role of genetics in individualized secondary prevention.

Conclusion

This review summarizes current genetic research on the different potential causes of cryptogenic stroke and discusses the possible applications of genetic tools in etiologic stratification and mechanistic investigation. Despite heterogeneous case definitions, limited sample sizes and ancestral diversity, and remaining constraints on mechanistic and clinical inference, genetic evidence is steadily improving our understanding of cryptogenic stroke. The integration of multiple research approaches may improve identification of underlying causes and provide a foundation for the future development of mechanism-informed management strategies in cryptogenic stroke.

Notes

Funding statement
The study was supported by the Project of Beijing Municipal Science and Technology Plan (Z241100009024046), the National Natural Science Foundation of China (82471304), the Beijing High-Level Innovation and Entrepreneurship Talent Support Program Young Top Talent Projects (G202522121), and the Young Talents Supporting Program of Capital Medical University (B2417). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Conflicts of interest
The authors have no financial conflicts of interest.
Author contribution
Conceptualization: Lanxin Li, Si Cheng, Jie Zhang. Study design: Lanxin Li, Si Cheng, Jie Zhang. Methodology: Lanxin Li, Si Cheng, Jie Zhang. Data collection: Lanxin Li. Investigation: Lanxin Li. Writing—original draft: Lanxin Li. Writing—review & editing: all authors. Funding acquisition: Si Cheng. Approval of final manuscript: all authors.
Acknowledgments
We gratefully acknowledge Servier Medical Art (https://smart.servier.com/) for providing some of the illustrative elements used in Figures 1 and 2. These elements were adapted and modified for the present figures under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).

Figure 1.
Research evolution of potential etiologies of cryptogenic stroke and the role of genetics in etiologic discovery and clinical translation. Boxes marked with a chromosome icon indicate findings or advances primarily supported by genetic or multi-omics evidence. *Including subsequent secondary analyses that identified left atrial enlargement as a potential marker of anticoagulation benefit. AF, atrial fibrillation; GWAS, genome-wide association study; EMBRACE, 30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation After a Cerebral Ischemic Event; CRYSTAL AF, Cryptogenic Stroke and Underlying Atrial Fibrillation; NAVIGATE ESUS, New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source; RE-SPECT ESUS, Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate versus Acetylsalicylic Acid in Patients with Embolic Stroke of Undetermined Source; AF-PRS, atrial fibrillation polygenic risk score; ARCADIA, Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke; ATTICUS, Apixaban for Treatment of Embolic Stroke of Undetermined Source; nsCAP, nonstenotic carotid artery plaque; PFO, patent foramen ovale; RoPE, Risk of Paradoxical Embolism; PASCAL, PFO-Associated Stroke Causal Likelihood; CLOSURE I, Evaluation of the STARFlex Septal Closure System in Patients with a Stroke and/or Transient Ischemic Attack due to Presumed Paradoxical Embolism through a Patent Foramen Ovale; PC trial, Clinical Trial Comparing Percutaneous Closure of Patent Foramen Ovale (PFO) Using the Amplatzer PFO Occluder with Medical Treatment in Patients with Cryptogenic Embolism; RESPECT, Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment; CLOSE, Patent Foramen Ovale Closure or Anticoagulants versus Antiplatelet Therapy to Prevent Stroke Recurrence; REDUCE, GORE HELEX Septal Occluder/GORE CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke or Imaging-Confirmed Transient Ischemic Attack in Patients With Patent Foramen Ovale; CHIP, clonal hematopoiesis of indeterminate potential; TOAST, Trial of Org 10172 in Acute Stroke Treatment; CCS, Causative Classification of Stroke System; ESUS, embolic stroke of undetermined source; mRNA, messenger RNA.
jos-2026-03923f1.jpg
Figure 2.
Potential translational framework of genetic and multi-omics evidence in cryptogenic stroke: mechanistic insights, clinical applications, limitations, and future directions. GWAS, genome-wide association study; IL-6, interleukin-6; CCL2, C-C motif chemokine ligand 2; TNF-α, tumor necrosis factor-α; IL-10, interleukin-10; PRS, polygenic risk score; CHIP, clonal hematopoiesis of indeterminate potential; RNA-seq, RNA sequencing.
jos-2026-03923f2.jpg
Table 1.
Monogenic causes of cryptogenic stroke reported beyond conventional diagnostic evaluation: genetic basis, mechanisms, and clinical features
Disease Disease category Stroke mechanism Gene Mode of inheritance Characteristic clinical features Treatment Ref
CADASIL Cerebral small vessel disease Small vessel diseases NOTCH3 AD Subcortical ischemic events, migraine with aura, mood disturbances and apathy, cognitive impairment and dementia Supportive [129,130]
CARASIL Cerebral small vessel disease Small vessel diseases HTRA1 AR Recurrent lacunar ischemic strokes, early-onset cognitive decline and dementia, premature diffuse alopecia, and spondylosis with low back pain Supportive [131]
CARASAL Cerebral small vessel disease Small vessel diseases CTSA AD Ischemic or hemorrhagic stroke, cognitive impairment, dementia, headache, migraine, vertigo, and movement disorders Supportive [132]
RVCLS Inherited systemic microangiopathy Small vessel diseases TREX1 AD Retinopathy, psychiatric symptoms, ischemic stroke or TIA, migraine, and renal dysfunction Supportive [65]
COL4A1/2-related brain small-vessel disease Cerebral small vessel disease Small vessel diseases COL4A1, COL4A2 AD Cerebral SVD, intracerebral hemorrhage, porencephaly, myopathy, ocular and renal involvement Supportive [133]
RNF213-related vasculopathy Progressive arteriopathy Large-artery diseases RNF213 AD (incomplete penetrance) Moyamoya disease, non-moyamoya intracranial stenosis, with systemic arterial involvement Surgical revascularization for moyamoya disease; individualized management [134]
Fabry disease Inherited lysosomal storage disorder Cerebral vasculopathy mediated by endothelial GL-3 accumulation GLA X-linked Angiokeratomas, neuropathic pain, hypohidrosis, and cardiac, renal, and ocular involvement Enzyme replacement therapy [69]
Homocystinuria Inherited metabolic disorder Vascular endothelial dysfunction CBS (most common); MTHFR, MTR, MTRR (related disorders) AR Recurrent thromboses, developmental delay, ectopia lentis and/or severe myopia, marfanoid skeletal features Vitamin supplementation; betaine; diet therapy; experimental enzyme replacement therapy [70]
Sickle cell disease Inherited hemoglobinopathies Sickled RBC adhesion, hemolysis-induced endothelial dysfunction, and cerebral vasculopathy HBB AR Chronic hemolytic anemia, recurrent vaso-occlusive pain, and multiorgan complications Hydroxyurea; chronic transfusion; exchange transfusion [135]
TTP Thrombotic microangiopathy ADAMTS13 deficiency with VWF-mediated platelet microthrombosis ADAMTS13 AR Young-onset stroke/TIA, neonatal jaundice with hemolysis and thrombocytopenia, pregnancy-associated complications Plasma infusion/replacement; ADAMTS13 replacement [136,137]
DADA2 Systemic vasculitis syndrome Vasculitis ADA2 AR Early-onset recurrent ischemic stroke, systemic inflammation and vasculitis, immunologic and hematologic abnormalities Tumor necrosis factor blockade [71]
PXE Inherited connective tissue disorder PPi deficiency-mediated arterial calcification and vasculopathy ABCC6 AR Premature atherosclerosis with skin and ocular involvement Supportive [138]
vEDS Inherited connective tissue disorder Arterial dissection COL3A1 AD Vascular fragility with arterial dissection risk Celiprolol (limited evidence) [139,140]
Marfan syndrome Inherited connective tissue disorder Arterial dissection and potential cardioembolism FBN1 AD Aortic root aneurysm, aortic dissection, ectopia lentis, skeletal overgrowth β-blockers and ARBs, preventive surgery [141]
Genetic cardiomyopathies* Hypertrophic and other inherited cardiomyopathies Cardioembolism TNNI3, JPH2, NEXN, TTN, PRKAG2, RYR2, among others AD Cardiomyopathy, arrhythmia, heart failure, intracardiac thrombus Supportive [67,110,142]
Mendelian forms of congenital heart disease* Congenital heart diseases Cardioembolism TBX5, TBX20, GATA6, among others AD Structural cardiac defects, arrhythmia, risk of thromboembolism Surgical correction [110,143]
Carney complex Multiple neoplasia syndrome Cardioembolism PRKAR1A AD Endocrine tumors, cardiac myxoma, pigmented skin lesions Surgery [144]
NF1 Inherited systemic disease Cerebral vasculopathy NF1 AD Neurocutaneous manifestations (neurofibromas, café-au-lait spots), skeletal abnormalities, and vascular involvement Surveillance and lesion-directed intervention, including surgical revascularization when indicated [145]
Ref, reference; CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; AD, autosomal dominant; CARASIL, cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy; AR, autosomal recessive; CARASAL, cathepsin A-related arteriopathy with strokes and leukoencephalopathy; RVCLS, retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations; TIA, transient ischemic attack; SVD, small vessel disease; GL-3, globotriaosylceramide; RBC, red blood cell; TTP, thrombotic thrombocytopenic purpura; VWF, von Willebrand factor; DADA2, adenosine deaminase 2 deficiency; PXE, pseudoxanthoma elasticum; PPi, inorganic pyrophosphate; vEDS, vascular Ehlers-Danlos syndrome; ARBs, angiotensin II receptor blockers; NF1, neurofibromatosis type 1.
* “Genetic cardiomyopathies” and “Mendelian forms of congenital heart disease” represent grouped categories rather than individual monogenic diagnoses. Genetic studies of patients with cryptogenic stroke identified several genes known to cause cardiomyopathies or congenital heart disease; these genes were grouped according to their corresponding disease entities. The terminology follows established definitions and classifications of cardiomyopathies and congenital heart disease. [142,143]
Table 2.
Mechanisms underlying disease susceptibility and stroke occurrence among genetically investigated etiologies of cryptogenic stroke
Etiologic category Mechanisms underlying disease susceptibility (representative genes) Mechanisms contributing to stroke occurrence
Atrial disease spectrum (AF or atrial cardiopathy) Structural remodeling and contractile dysfunction of atrial myocardium (e.g., TTN, MYH6, SYNPO2L) [14,23]; atrial fibrosis and extracellular matrix remodeling (e.g., TGF-β signaling-related genes) [146]; electrical and electromechanical coupling abnormalities, including ion-channel and calcium-handling dysregulation (e.g., KCNN3, CASQ2, CAMK2D) [14,23]; cardiac development and transcriptional regulation (e.g., PITX2, TBX5) [14,23]; autonomic nervous system modulation (genetic evidence limited) [147] Atrial mechanical dysfunction, blood stasis, and left atrial appendage thrombogenesis [148]; endothelial dysfunction [149]; hypercoagulability and thromboinflammation [148]
nsCAP Vulnerable nonstenotic plaque with intraplaque hemorrhage, lipid-rich necrotic core, inflammation, and surface irregularity (genetic evidence limited) [150,151] Artery-to-artery embolism from vulnerable nonstenotic plaque [152]
PFO Abnormal atrial septation and cardiac development (e.g., NKX2-5) [60] Right-to-left shunt-mediated paradoxical embolism [153]; in situ thrombus formation within the PFO channel or right atrial septum [154]; inherited thrombophilia and endothelial dysfunction potentially promoting paradoxical embolism [62-64]
CHIP Age-related acquisition of somatic driver mutations promotes clonal expansion of hematopoietic stem cells (e.g., DNMT3A, TET2, ASXL1, JAK2) [74,79] Proinflammatory activation and accelerated atherosclerosis [77,79]; possible association with atrial remodeling and AF [78]; potential prothrombotic effects in selected patients [79]
Cancer Consideration of genetic and molecular mechanisms by specific cancer type Cancer-associated hypercoagulability/coagulopathy [155,156]; nonbacterial thrombotic endocarditis [157]; neutrophil extracellular trap formation-mediated immunothrombosis [155,156]; tumor-mediated procoagulant pathways (e.g., tissue factor, mucins, extracellular vesicles) [155,156]; endothelial activation and thromboinflammation [155,156]
AF, atrial fibrillation; nsCAP, nonstenotic carotid artery plaque; PFO, patent foramen ovale; CHIP, clonal hematopoiesis of indeterminate potential; TGF-β, transforming growth factor-β.
Table 3.
Clinical implications of genetic evidence across major etiologies of cryptogenic stroke
Potential etiology Clinical evaluation clues Imaging clues Current diagnostic strategies Main clinical challenge Genetic evidence
Current findings Current clinical translation Future applications
AF Sudden maximal neurological deficit; cortical symptoms; history of palpitations or arrhythmia [158] Neuroimaging: multiple or sequential infarcts across arterial territories; cortical involvement; spatially dispersed infarct pattern [158] Short-term ECG; prolonged monitoring [17]; implantable loop recorder [16] Detection of occult AF, [16] determination of AF-related stroke causality [162] Strong heritability; >350 loci identified [14]; PRS improves AF prediction and may aid discrimination of cardioembolic stroke [14,26] No established genetics-guided clinical application [26,27] Integrated PRS-clinical models for AF prediction and targeted monitoring [27]
Cardiac imaging: increased LA size (e.g., increased LAVI), [159] impaired LA function (e.g., reduced LASr), [160] reduced LAA functional indices (e.g., LAAev) [161]
Atrial cardiopathy Left atrial enlargement; elevated NT-proBNP; abnormal P-wave indices [11] Neuroimaging: no specific neuroimaging phenotype established ECG and circulating markers [24]; echocardiographic and MRI assessment of LA structure and function [30,31] Lack of standardized diagnostic criteria [29] and causal validation [165] Limited but emerging evidence from cardiac trait GWAS/Mendelian randomization [24] and atrial remodeling genes [34-37] No genetics-guided clinical application Genetics-integrated phenotyping using imaging and biomarkers to refine atrial cardiopathy subtypes [34,36]
Cardiac imaging: LA fibrosis on LGE-CMR, [163] LA structural and functional abnormalities, LA enlargement and impaired LA function (e.g., increased LAVI and reduced LASr) [164]
nsCAP No specific clinical clues established Neuroimaging: ipsilateral complicated nonstenotic carotid plaque with high-risk features [39,166] CTA/vessel wall MRI [167,168]; ipsilateral plaque burden [39]; high-risk plaque features [169] Overlooked nonstenotic plaques and uncertain high-risk features [152,166] Potential causal evidence and genetic overlap with LAAS [25]; limited evidence for genes related to carotid plaque phenotypes [43-47] No genetics-guided clinical application Integration of imaging and genetic data to identify plaque-related cryptogenic stroke subtypes [39,167]
PFO Younger age; few conventional vascular risk factors [170]; venous thromboembolism [171]; possible migraine with aura [172] Neuroimaging: embolic infarct patterns including superficial/cortical or multiple infarcts, often without persistent arterial occlusion [173,174] TEE/TCD-based shunt assessment [170]; RoPE score and PASCAL classification [170]; high-risk anatomical features and embolic infarct pattern [172] Difficulty distinguishing causal from incidental PFO and identifying high-risk features [170,175] Limited evidence from candidate genes related to cardiac development/structure [176]; possible added risk when PFO coexists with MTHFR-related abnormalities and endothelial dysfunction [64] No genetics-guided clinical application Integrated structural, genetic, and prothrombotic profiling to identify pathogenic PFO subtypes [170,176]
Cardiac imaging: large right-to-left shunt, atrial septal aneurysm [171]
CHIP No specific clinical phenotype established Neuroimaging: no specific neuroimaging phenotype established Peripheral-blood sequencing for CHIP-driver mutations after excluding overt hematologic neoplasia [74] Uncertain causality and lack of validated risk stratification [79] Associations with stroke, [75] atherosclerosis, [77] AF, [78] short-term stroke recurrence [76]; increased prevalence in young patients with stroke enriched for cryptogenic stroke [79] CHIP testing available, but clinical utility in stroke remains uncertain [79] Potential risk prediction and individualized management [76,79]
Cancer Active or occult cancer indicators; unexplained weight loss; elevated D-dimer [84] Neuroimaging: multiple acute infarcts involving multiple vascular territories, particularly the three-territory sign [177] D-dimer and embolic imaging patterns [82,178]; targeted cancer screening [178] Detecting occult cancer and determining its contribution to stroke [178] Limited but emerging evidence from peripheral-blood transcriptomic study showing distinct mRNA profiles in patients with cancer-associated stroke [85] No genetics-guided clinical application Potential use of blood transcriptomic biomarkers to support occult-cancer detection and etiologic classification [85]
The clinical evaluation clues and neuroimaging clues show representative findings reported in the literature and should be interpreted as supportive rather than mandatory features. Current clinical translation refers specifically to the clinical application of genetic evidence, rather than the overall clinical management of each etiology.
AF, atrial fibrillation; LA, left atrial; LAVI, left atrial volume index; LASr, left atrial reservoir strain; LAA, left atrial appendage; LAAev, left atrial appendage emptying velocity; ECG, electrocardiography; PRS, polygenic risk score; NT-proBNP, N-terminal pro-B-type natriuretic peptide; LGE-CMR, late gadolinium enhancement cardiac magnetic resonance; MRI, magnetic resonance imaging; GWAS, genome-wide association study; nsCAP, nonstenotic carotid artery plaque; CTA, computed tomography angiography; LAAS, large-artery atherosclerotic stroke; PFO, patent foramen ovale; TEE, transesophageal echocardiography; TCD, transcranial Doppler; RoPE, Risk of Paradoxical Embolism; PASCAL, PFO-Associated Stroke Causal Likelihood; CHIP, clonal hematopoiesis of indeterminate potential; mRNA, messenger RNA.

References

1. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet Neurol 2021;20:795-820.
pmid pmc
2. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke 2021;52:e364-e467.
pmid
3. Yaghi S, Elkind MSV. Cryptogenic stroke: a diagnostic challenge. Neurol Clin Pract 2014;4:386-393.
pmid pmc
4. Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke 2001;32:2735-2740.
crossref pmid
5. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
crossref pmid
6. Guercini F, Acciarresi M, Agnelli G, Paciaroni M. Cryptogenic stroke: time to determine aetiology. J Thromb Haemost 2008;6:549-554.
crossref pmid
7. Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014;13:429-438.
crossref pmid
8. Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018;378:2191-2201.
crossref pmid
9. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 2019;380:1906-1917.
pmid
10. Geisler T, Keller T, Martus P, Poli K, Serna-Higuita LM, Schreieck J, et al. Apixaban versus aspirin for embolic stroke of undetermined source. NEJM Evid 2024;3:EVIDoa2300235.
crossref pmid
11. Kamel H, Longstreth WT Jr, Tirschwell DL, Kronmal RA, Marshall RS, Broderick JP, et al. Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy: the ARCADIA randomized clinical trial. JAMA 2024;331:573-581.
pmid pmc
12. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet 2018;19:581-590.
crossref pmid pdf
13. Atchaneeyasakul K, Bates KE, Toledo A, Griswold AJ, Ramdas K, Watanabe M, et al. Utilizing RNA sequencing to identify gene expression markers of stroke-causing thrombi origin: a pilot study. J Stroke Cerebrovasc Dis 2024;33:107518.
crossref pmid
14. Roselli C, Surakka I, Olesen MS, Sveinbjornsson G, Marston NA, Choi SH, et al. Meta-analysis of genome-wide associations and polygenic risk prediction for atrial fibrillation in more than 180,000 cases. Nat Genet 2025;57:539-547.
pmid pmc
15. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014;370:2467-2477.
crossref pmid
16. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014;370:2478-2486.
crossref pmid
17. Grond M, Jauss M, Hamann G, Stark E, Veltkamp R, Nabavi D, et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke 2013;44:3357-3364.
crossref pmid
18. Mele F, Scopelliti G, La Volpe L, Ferrari Aggradi C, Molitierno N, Cova I, et al. Prediction scores of subclinical atrial fibrillation in patients with cryptogenic stroke and transient ischemic attack. Int J Stroke 2025;20:1150-1158.
crossref pmid pdf
19. Gudbjartsson DF, Arnar DO, Helgadottir A, Gretarsdottir S, Holm H, Sigurdsson A, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007;448:353-357.
crossref pmid pdf
20. Tucker NR, Ellinor PT. Emerging directions in the genetics of atrial fibrillation. Circ Res 2014;114:1469-1482.
crossref pmid pmc
21. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 2018;562:203-209.
crossref pmid pmc pdf
22. All of Us Research Program Genomics Investigators. Genomic data in the All of Us Research Program. Nature 2024;627:340-346.
pmid pmc
23. Gajendragadkar PR, Von Ende A, Murgia F, Offer A, Camm CF, Wijesurendra RS, et al. Mechanistic pathways underlying genetic predisposition to atrial fibrillation are associated with different cardiac phenotypes and cardioembolic stroke risk. Circ Genom Precis Med 2025;18:e004932.
crossref pmid pmc
24. Frerich S, Malik R, Georgakis MK, Sinner MF, Kittner SJ, Mitchell BD, et al. Cardiac risk factors for stroke: a comprehensive Mendelian randomization study. Stroke 2022;53:e130-e135.
crossref pmid
25. Georgakis MK, Parodi L, Frerich S, Mayerhofer E, Tsivgoulis G, Pirruccello JP, et al. Genetic architecture of stroke of undetermined source: overlap with known stroke etiologies and associations with modifiable risk factors. Ann Neurol 2022;91:640-651.
crossref pmid pdf
26. Weng LC, Khurshid S, Gunn S, Trinquart L, Lunetta KL, Xu H, et al. Clinical and genetic atrial fibrillation risk and discrimination of cardioembolic from noncardioembolic stroke. Stroke 2023;54:1777-1785.
crossref pmid pmc
27. Tack RWP, Tan BYQ, Senff JR, Prapiadou S, Kimball TN, Khurshid S, et al. Predicting atrial fibrillation after stroke by combining polygenic risk scores and clinical features. Stroke 2025;56:878-886.
crossref pmid pmc
28. Hirsh BJ, Copeland-Halperin RS, Halperin JL. Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences. J Am Coll Cardiol 2015;65:2239-2251.
pmid
29. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterisation, and clinical implication. J Arrhythm 2016;32:247-278.
pmid pmc
30. Habibi M, Zareian M, Ambale Venkatesh B, Samiei S, Imai M, Wu C, et al. Left atrial mechanical function and incident ischemic cerebrovascular events independent of AF: insights from the MESA study. JACC Cardiovasc Imaging 2019;12:2417-2427.
pmid pmc
31. Johansen MC, Doria de Vasconcellos H, Nazarian S, Lima JAC, Gottesman RF. The investigation of left atrial structure and stroke etiology: the I-LASER study. J Am Heart Assoc 2021;10:e018766.
crossref pmid pmc
32. Healey JS, Gladstone DJ, Swaminathan B, Eckstein J, Mundl H, Epstein AE, et al. Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation: secondary analysis of the NAVIGATE ESUS randomized clinical trial. JAMA Neurol 2019;76:764-773.
crossref pmid pmc
33. Vad OB, Paludan-Müller C, Diederichsen SZ, McKaige EA, Monfort LM, Lundegaard PR, et al. Genetic determinants of left atrial function are associated with stroke. J Am Heart Assoc 2024;13:e037490.
crossref pmid pmc
34. Yamaguchi N, Xiao J, Narke D, Shaheen D, Lin X, Offerman E, et al. Cardiac pressure overload decreases ETV1 expression in the left atrium, contributing to atrial electrical and structural remodeling. Circulation 2021;143:805-820.
crossref pmid
35. Ghazizadeh Z, Kiviniemi T, Olafsson S, Plotnick D, Beerens ME, Zhang K, et al. Metastable atrial state underlies the primary genetic substrate for MYL4 mutation-associated atrial fibrillation. Circulation 2020;141:301-312.
crossref pmid
36. Wang Y, Wang J, Shi L, Chen X, Li D, Cui C, et al. CIB2 Is a novel endogenous repressor of atrial remodeling. Circulation 2023;147:1758-1776.
crossref pmid
37. Collins MM, Ahlberg G, Hansen CV, Guenther S, Marín-Juez R, Sokol AM, et al. Early sarcomere and metabolic defects in a zebrafish pitx2c cardiac arrhythmia model. Proc Natl Acad Sci U S A 2019;116:24115-24121.
crossref pmid pmc
38. Freilinger TM, Schindler A, Schmidt C, Grimm J, Cyran C, Schwarz F, et al. Prevalence of nonstenosing, complicated atherosclerotic plaques in cryptogenic stroke. JACC Cardiovasc Imaging 2012;5:397-405.
crossref pmid
39. Ospel JM, Singh N, Marko M, Almekhlafi M, Dowlatshahi D, Puig J, et al. Prevalence of ipsilateral nonstenotic carotid plaques on computed tomography angiography in embolic stroke of undetermined source. Stroke 2020;51:1743-1749.
crossref pmid
40. Ntaios G, Swaminathan B, Berkowitz SD, Gagliardi RJ, Lang W, Siegler JE, et al. Efficacy and safety of rivaroxaban versus aspirin in embolic stroke of undetermined source and carotid atherosclerosis. Stroke 2019;50:2477-2485.
crossref pmid
41. Rapillo CM, Giuricin A, Sarti C, Nesi M, Marcheselli S, Lombardo I, et al. Prevalence of carotid plaques with high-risk features in embolic stroke of undetermined source: systematic review and meta-analysis. Int J Stroke 2025;20:636-645.
crossref pmid pdf
42. Kamtchum-Tatuene J, Wilman A, Saqqur M, Shuaib A, Jickling GC. Carotid plaque with high-risk features in embolic stroke of undetermined source: systematic review and meta-analysis. Stroke 2020;51:311-314.
crossref pmid
43. Song J, Jiang X, Cao Y, Juan J, Wu T, Hu Y. Interaction between an ATP-binding cassette A1 (ABCA1) variant and egg consumption for the risk of ischemic stroke and carotid atherosclerosis: a family-based study in the Chinese population. J Atheroscler Thromb 2019;26:835-845.
pmid pmc
44. Wang L, Yanuck D, Beecham A, Gardener H, Slifer S, Blanton SH, et al. A candidate gene study revealed sex-specific association between the OLR1 gene and carotid plaque. Stroke 2011;42:588-592.
crossref pmid pmc
45. Alloza I, Salegi A, Mena J, Navarro RT, Martin C, Aspichueta P, et al. BIRC6 is associated with vulnerability of carotid atherosclerotic plaque. Int J Mol Sci 2020;21:9387.
crossref pmid pmc
46. Yi XY, Liao DX, Wang C, Cheng W, Fu XQ, Zhang B. Cytochrome P450 genetic variants and their metabolite levels associated with plaque stability in patients with ischemic stroke. J Atheroscler Thromb 2016;23:330-338.
crossref pmid
47. Liao YC, Lin HF, Guo YC, Yu ML, Liu CK, Juo SH. Sex-differential genetic effect of phosphodiesterase 4D (PDE4D) on carotid atherosclerosis. BMC Med Genet 2010;11:93.
crossref pmid pmc pdf
48. Webster MW, Chancellor AM, Smith HJ, Swift DL, Sharpe DN, Bass NM, et al. Patent foramen ovale in young stroke patients. Lancet 1988;2:11-12.
crossref pmid
49. Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988;318:1148-1152.
crossref pmid
50. Mac Grory B, Ohman EM, Feng W, Xian Y, Yaghi S, Kamel H, et al. Advances in the management of cardioembolic stroke associated with patent foramen ovale. BMJ 2022;376:e063161.
crossref pmid
51. Cabanes L, Mas JL, Cohen A, Amarenco P, Cabanes PA, Oubary P, et al. Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke 1993;24:1865-1873.
crossref pmid
52. Kent DM, Ruthazer R, Weimar C, Mas JL, Serena J, Homma S, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology 2013;81:619-625.
crossref pmid pmc
53. Kent DM, Saver JL, Kasner SE, Nelson J, Carroll JD, Chatellier G, et al. Heterogeneity of treatment effects in an analysis of pooled individual patient data from randomized trials of device closure of patent foramen ovale after stroke. JAMA 2021;326:2277-2286.
pmid pmc
54. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012;366:991-999.
crossref pmid
55. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013;368:1083-1091.
crossref pmid
56. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, Mac-Donald LA, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013;368:1092-1100.
crossref pmid
57. Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 2017;377:1022-1032.
crossref pmid
58. Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 2017;377:1011-1021.
pmid
59. Søndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 2017;377:1033-1042.
crossref pmid
60. Elliott DA, Kirk EP, Yeoh T, Chandar S, McKenzie F, Taylor P, et al. Cardiac homeobox gene NKX2-5 mutations and congenital heart disease: associations with atrial septal defect and hypoplastic left heart syndrome. J Am Coll Cardiol 2003;41:2072-2076.
pmid
61. Kirk EP, Hyun C, Thomson PC, Lai D, Castro ML, Biben C, et al. Quantitative trait loci modifying cardiac atrial septal morphology and risk of patent foramen ovale in the mouse. Circ Res 2006;98:651-658.
crossref pmid
62. Morris JG, Singh S, Fisher M. Testing for inherited thrombophilias in arterial stroke: can it cause more harm than good? Stroke 2010;41:2985-2990.
crossref pmid
63. Botto N, Spadoni I, Giusti S, Ait-Ali L, Sicari R, Andreassi MG. Prothrombotic mutations as risk factors for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale. Stroke 2007;38:2070-2073.
crossref pmid
64. Sgarra L, Bortone AS, Potenza MA, Nacci C, De Salvia MA, Acquaviva T, et al. Endothelial dysfunction may link interatrial septal abnormalities and MTHFR-inherited defects to cryptogenic stroke predisposition. Biomolecules 2020;10:861.
crossref pmid pmc
65. Bersano A, Kraemer M, Burlina A, Mancuso M, Finsterer J, Sacco S, et al. Heritable and non-heritable uncommon causes of stroke. J Neurol 2021;268:2780-2807.
crossref pmid pdf
66. Dichgans M. Genetics of ischaemic stroke. Lancet Neurol 2007;6:149-161.
crossref pmid
67. Mania-Pâris L, Vitobello A, Safraou H, Tran Mau-Them F, Duffourd Y, Nambot S, et al. Systematic genetic assessment in young patients with cryptogenic stroke: the ES-EASY project. Stroke 2026;57:148-156.
crossref pmid
68. Yaghi S, Bernstein RA, Passman R, Okin PM, Furie KL. Cryptogenic stroke: research and practice. Circ Res 2017;120:527-540.
pmid
69. Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab 2018;124:189-203.
pmid
70. Althubity AA. Homocystinuria: advances in metabolic and molecular therapies targeting homocysteine pathways (review). Mol Med Rep 2026;33:34.
crossref pmid
71. Soldatos A, Toro C, Hoffmann P, Romeo T, Deuitch N, Brofferio A, et al. TNF-blockade for primary stroke prevention in adenosine deaminase 2 deficiency: a case series. Neurol Neuroimmunol Neuroinflamm 2023;10:e200073.
pmid pmc
72. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014;371:2488-2498.
crossref pmid pmc
73. Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015;126:9-16.
crossref pmid pmc pdf
74. Libby P, Sidlow R, Lin AE, Gupta D, Jones LW, Moslehi J, et al. Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer: JACC review topic of the week. J Am Coll Cardiol 2019;74:567-577.
pmid pmc
75. Bhattacharya R, Zekavat SM, Haessler J, Fornage M, Raffield L, Uddin MM, et al. Clonal hematopoiesis is associated with higher risk of stroke. Stroke 2022;53:788-797.
pmid
76. Qiu X, Dai Y, Cheng S, Gu HQ, Jiang Y, Meng X, et al. Somatic mutation contributing to clonal haematopoiesis is a risk factor of recurrent stroke in first-ever acute ischaemic stroke: a prospective cohort study. Stroke Vasc Neurol 2023;8:103-110.
crossref pmid
77. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 2017;377:111-121.
crossref pmid pmc
78. Ahn HJ, An HY, Ryu G, Lim J, Sun C, Song H, et al. Clonal haematopoiesis of indeterminate potential and atrial fibrillation: an east Asian cohort study. Eur Heart J 2024;45:778-790.
crossref pmid pdf
79. Mayerhofer E, Strecker C, Becker H, Georgakis MK, Uddin MM, Hoffmann MM, et al. Prevalence and therapeutic implications of clonal hematopoiesis of indeterminate potential in young patients with stroke. Stroke 2023;54:938-946.
crossref pmid pmc
80. Kim SG, Hong JM, Kim HY, Lee J, Chung PW, Park KY, et al. Ischemic stroke in cancer patients with and without conventional mechanisms: a multicenter study in Korea. Stroke 2010;41:798-801.
crossref pmid
81. Rioux B, Touma L, Nehme A, Gore G, Keezer MR, Gioia LC. Frequency and predictors of occult cancer in ischemic stroke: a systematic review and meta-analysis. Int J Stroke 2021;16:12-19.
crossref pmid pdf
82. Gon Y, Sakaguchi M, Takasugi J, Kawano T, Kanki H, Watanabe A, et al. Plasma D-dimer levels and ischaemic lesions in multiple vascular regions can predict occult cancer in patients with cryptogenic stroke. Eur J Neurol 2017;24:503-508.
crossref pmid pdf
83. Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Tagawa ST, et al. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood 2019;133:781-789.
crossref pmid pdf
84. Tieck MP, Single C, Poli S, Kowarik MC, Ziemann U, Mengel A, et al. Screening tools for malignancy in patients with cryptogenic stroke: systematic review. Eur Stroke J 2025;10:665-674.
crossref pmid pmc pdf
85. Navi BB, Mathias R, Sherman CP, Wolfe J, Kamel H, Tagawa ST, et al. Cancer-related ischemic stroke has a distinct blood mRNA expression profile. Stroke 2019;50:3259-3264.
crossref pmid pmc
86. Lutgens E, Atzler D, Döring Y, Duchene J, Steffens S, Weber C. Immunotherapy for cardiovascular disease. Eur Heart J 2019;40:3937-3946.
crossref pmid pdf
87. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119-1131.
crossref pmid
88. Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol 2015;12:230-243.
crossref pmid pdf
89. Shi K, Tian DC, Li ZG, Ducruet AF, Lawton MT, Shi FD. Global brain inflammation in stroke. Lancet Neurol 2019;18:1058-1066.
crossref pmid
90. Munshi A, Rajeshwar K, Kaul S, Al-Hazzani A, Alshatwi AA, Sai Babu M, et al. Interleukin-10-1082 promoter polymorphism and ischemic stroke risk in a South Indian population. Cytokine 2010;52:221-224.
crossref pmid
91. Munshi A, Rajeshwar K, Kaul S, Al-Hazzani A, Alshatwi AA, Shafi G, et al. Association of tumor necrosis factor-α and matrix metalloproteinase-3 gene variants with stroke. Eur J Neurol 2011;18:1053-1059.
crossref pmid
92. Georgakis MK, Gill D, Rannikmäe K, Traylor M, Anderson CD, Lee JM, et al. Genetically determined levels of circulating cytokines and risk of stroke. Circulation 2019;139:256-268.
crossref pmid pmc
93. Jickling GC, Xu H, Stamova B, Ander BP, Zhan X, Tian Y, et al. Signatures of cardioembolic and large-vessel ischemic stroke. Ann Neurol 2010;68:681-692.
crossref pmid pmc
94. Mishra A, Malik R, Hachiya T, Jürgenson T, Namba S, Posner DC, et al. Stroke genetics informs drug discovery and risk prediction across ancestries. Nature 2022;611:115-123.
pmid pmc
95. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat Genet 2018;50:524-537.
pmid pmc
96. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 2018;50:1219-1224.
crossref pmid pmc pdf
97. Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical instruments. Genome Med 2020;12:44.
crossref pmid pdf
98. Gibson JT, Rudd JHF. Polygenic risk scores in atrial fibrillation: associations and clinical utility in disease prediction. Heart Rhythm 2024;21:913-918.
crossref pmid
99. Chatterjee N, Shi J, García-Closas M. Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nat Rev Genet 2016;17:392-406.
crossref pmid pmc pdf
100. Yang Y, Guo K, Zhang Y, Fang Z, Lin H, Grosser M, et al. MetaGeno: a chromosome-wise multi-task genomic framework for ischaemic stroke risk prediction. Brief Bioinform 2025;26:bbaf348.
crossref pmid pmc pdf
101. Truong B, Hull LE, Ruan Y, Huang QQ, Hornsby W, Martin H, et al. Integrative polygenic risk score improves the prediction accuracy of complex traits and diseases. Cell Genom 2024;4:100523.
crossref pmid pmc
102. Abraham G, Malik R, Yonova-Doing E, Salim A, Wang T, Danesh J, et al. Genomic risk score offers predictive performance comparable to clinical risk factors for ischaemic stroke. Nat Commun 2019;10:5819.
crossref pmid pmc pdf
103. Li H, Zeng J, Snyder MP, Zhang S. Modeling gene interactions in polygenic prediction via geometric deep learning. Genome Res 2025;35:178-187.
crossref pmid pmc
104. Kelemen M, Xu Y, Jiang T, Zhao JH, Anderson CA, Wallace C, et al. Performance of deep-learning-based approaches to improve polygenic scores. Nat Commun 2025;16:5122.
crossref pmid pmc pdf
105. Luo Y, Zhang N, Yang J, Cui M, Tsoi KKF, Lip GYH, et al. AI-based multiomics profiling reveals complementary omics contributions to personalized prediction of cardiovascular disease. Nat Commun 2026;17:2269.
crossref pmid pmc pdf
106. Cai X, Li H, Cao X, Ma X, Zhu W, Xu L, et al. Integrating transcriptomic and polygenic risk scores to enhance predictive accuracy for ischemic stroke subtypes. Hum Genet 2025;144:43-54.
crossref pmid pdf
107. Labarga A, Martínez-Gonzalez J, Barajas M. Integrative multiomics analysis for etiology classification and biomarker discovery in stroke: advancing towards precision medicine. Biology (Basel) 2024;13:338.
crossref pmid pmc
108. Lambert AT, Sætre DO, Ratajczak-Tretel B, Gleditsch J, Høie G, Al-Ani R, et al. Imaging features for the identification of atrial fibrillation in cryptogenic stroke patients. J Neurol 2024;271:5343-5356.
crossref pmid pmc pdf
109. Yamamoto Y, Nagakane Y, Tanaka E, Yamada T, Fujinami J, Ohara T. How topographic diffusion-weighted imaging patterns can predict the potential embolic source. Clin Neuroradiol 2024;34:363-371.
crossref pmid pdf
110. Yuan WZ, Shang L, Tian DS, Wu SW, You Y, Tian CL, et al. Monogenic basis of young-onset cryptogenic stroke: a multicenter study. Ann Transl Med 2022;10:512.
crossref pmid pmc
111. Ilinca A, Martinez-Majander N, Samuelsson S, Piccinelli P, Truvé K, Cole J, et al. Whole-exome sequencing in 22 young ischemic stroke patients with familial clustering of stroke. Stroke 2020;51:1056-1063.
crossref pmid pmc
112. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-424.
crossref pmid pmc pdf
113. Fitzgerald S, Dai D, Wang S, Douglas A, Kadirvel R, Layton KF, et al. Platelet-rich emboli in cerebral large vessel occlusion are associated with a large artery atherosclerosis source. Stroke 2019;50:1907-1910.
pmid pmc
114. Juega J, Palacio-Garcia C, Rodriguez M, Deck M, Rodriguez-Luna D, Requena M, et al. Monocyte-to-lymphocyte ratio in clot analysis as a marker of cardioembolic stroke etiology. Transl Stroke Res 2022;13:949-958.
crossref pmid pdf
115. Ay H, Benner T, Arsava EM, Furie KL, Singhal AB, Jensen MB, et al. A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. Stroke 2007;38:2979-2984.
crossref pmid
116. Wang Y, Guo J, Ni G, Yang J, Visscher PM, Yengo L. Theoretical and empirical quantification of the accuracy of polygenic scores in ancestry divergent populations. Nat Commun 2020;11:3865.
crossref pmid pmc pdf
117. Tam V, Patel N, Turcotte M, Bossé Y, Paré G, Meyre D. Benefits and limitations of genome-wide association studies. Nat Rev Genet 2019;20:467-484.
crossref pmid pdf
118. Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, et al. 10 years of GWAS discovery: biology, function, and translation. Am J Hum Genet 2017;101:5-22.
crossref pmid pmc
119. Duan XP, Qin BD, Jiao XD, Liu K, Wang Z, Zang YS. New clinical trial design in precision medicine: discovery, development and direction. Signal Transduct Target Ther 2024;9:57.
crossref pmid pmc pdf
120. Duncan L, Shen H, Gelaye B, Meijsen J, Ressler K, Feldman M, et al. Analysis of polygenic risk score usage and performance in diverse human populations. Nat Commun 2019;10:3328.
crossref pmid pmc pdf
121. Lindgren AG, Braun RG, Juhl Majersik J, Clatworthy P, Mainali S, Derdeyn CP, et al. International stroke genetics consortium recommendations for studies of genetics of stroke outcome and recovery. Int J Stroke 2022;17:260-268.
crossref pmid pdf
122. Majersik JJ, Cole JW, Golledge J, Rost NS, Chan YF, Gurol ME, et al. Recommendations from the international stroke genetics consortium, part 1: standardized phenotypic data collection. Stroke 2015;46:279-284.
crossref pmid
123. Rost NS, Meschia JF, Gottesman R, Wruck L, Helmer K, Greenberg SM; DISCOVERY Investigators. Cognitive impairment and dementia after stroke: design and rationale for the DISCOVERY study. Stroke 2021;52:e499-e516.
crossref pmid pmc
124. Hsieh YC, Seshadri S, Chung WT, Hsieh FI, Hsu YH, Lin HJ, et al. Association between genetic variant on chromosome 12p13 and stroke survival and recurrence: a one year prospective study in Taiwan. J Biomed Sci 2012;19:1.
crossref pmid pmc pdf
125. Lee JY, Park JM, Lee J, Choi JC, Lee KJ, Sung J, et al. Building the future of precision medicine in stroke management: design and cohort profiles of the GENESIS-K study (abstract number: ESOC2026A1666). Eur Stroke J 2026;11(Suppl 1):i452.

126. Nederkoorn PJ, van Dijk EJ, Koudstaal PJ, Luijckx GJ, van Oostenbrugge RJ, Visser MC, et al. The Dutch String-of-Pearls Stroke Study: protocol of a large prospective multicenter genetic cohort study. Int J Stroke 2015;10:120-122.
crossref pmid pdf
127. Cheng S, Xu Z, Bian S, Chen X, Shi Y, Li Y, et al. The STROMICS genome study: deep whole-genome sequencing and analysis of 10K Chinese patients with ischemic stroke reveal complex genetic and phenotypic interplay. Cell Discov 2023;9:75.
crossref pmid pmc pdf
128. Cheng S, Xu Z, Liu Y, Lin J, Jiang Y, Wang Y, et al. Whole genome sequencing of 10K patients with acute ischaemic stroke or transient ischaemic attack: design, methods and baseline patient characteristics. Stroke Vasc Neurol 2021;6:291-297.
crossref pmid
129. Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. CADASIL. Lancet Neurol 2009;8:643-653.
crossref pmid
130. Yuan L, Chen X, Jankovic J, Deng H. CADASIL: a NOTCH3-associated cerebral small vessel disease. J Adv Res 2024;66:223-235.
crossref pmid pmc
131. Tikka S, Baumann M, Siitonen M, Pasanen P, Pöyhönen M, Myllykangas L, et al. CADASIL and CARASIL. Brain Pathol 2014;24:525-544.
pmid pmc
132. Mancuso M, Arnold M, Bersano A, Burlina A, Chabriat H, Debette S, et al. Monogenic cerebral small-vessel diseases: diagnosis and therapy. Consensus recommendations of the European Academy of Neurology. Eur J Neurol 2020;27:909-927.
crossref pmid pdf
133. Giau VV, Bagyinszky E, Youn YC, An SSA, Kim SY. Genetic factors of cerebral small vessel disease and their potential clinical outcome. Int J Mol Sci 2019;20:4298.
crossref pmid pmc
134. Bang OY, Chung JW, Kim DH, Won HH, Yeon JY, Ki CS, et al. Moyamoya disease and spectrums of RNF213 vasculopathy. Transl Stroke Res 2020;11:580-589.
crossref pmid pdf
135. Brandow AM, Liem RI. Advances in the diagnosis and treatment of sickle cell disease. J Hematol Oncol 2022;15:20.
crossref pmid pmc pdf
136. Picod A, Joly BS, Veyradier A, Coppo P. Thrombotic thrombocytopenic purpura: a missed cause in stroke prevention guidelines. Stroke 2025;56:1104-1105.
crossref pmid
137. Kremer Hovinga JA, George JN. Hereditary thrombotic thrombocytopenic purpura. N Engl J Med 2019;381:1653-1662.
crossref pmid
138. Pfau K, Lengyel I, Ossewaarde-van Norel J, van Leeuwen R, Risseeuw S, Leftheriotis G, et al. Pseudoxanthoma elasticum - genetics, pathophysiology, and clinical presentation. Prog Retin Eye Res 2024;102:101274.
crossref pmid pmc
139. Buso G, Corvini F, Fusco EM, Messina M, Cherubini F, Laera N, et al. Current evidence and future perspectives in the medical management of vascular Ehlers-Danlos syndrome: focus on vascular prevention. J Clin Med 2024;13:4255.
crossref pmid pmc
140. Green CE, Albaba S, Sobey GJ, Bowen JM, Donnelly DE, Colombi M, et al. Vascular Ehlers Danlos syndrome and chromosome 2q32 microdeletion syndrome. Eur J Hum Genet 2025;33:1309-1315.
crossref pmid pmc pdf
141. Milewicz DM, Braverman AC, De Backer J, Morris SA, Boileau C, Maumenee IH, et al. Marfan syndrome. Nat Rev Dis Primers 2021;7:64.
crossref pmid pmc pdf
142. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006;113:1807-1816.
crossref
143. Zaidi S, Brueckner M. Genetics and genomics of congenital heart disease. Circ Res 2017;120:923-940.
crossref pmid pmc
144. Bouys L, Bertherat J. Management of endocrine disease: Carney complex: clinical and genetic update 20 years after the identification of the CNC1 (PRKAR1A) gene. Eur J Endocrinol 2021;184:R99-R109.
crossref pmid
145. Rosser TL, Vezina G, Packer RJ. Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1. Neurology 2005;64:553-555.
crossref pmid
146. Chen C, Chen P, Yu W, Zhao L, Yang Y, Qu H, et al. TGF-β-driven atrial fibrosis in atrial fibrillation: from mechanistic insights to targeted therapies. Aging Dis 2026;17:2509-2528.

147. D’Elia NW, Kistler PM, Voskoboinik A. Atrial fibrillation in the young: pathogenesis and clinical implications. JACC Clin Electrophysiol 2025;11:1051-1066.
pmid
148. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 2009;373:155-166.
crossref pmid
149. Khan AA, Thomas GN, Lip GYH, Shantsila A. Endothelial function in patients with atrial fibrillation. Ann Med 2020;52:1-11.
crossref pmid pmc
150. Larson AS, Brinjikji W, Lekah A, Klaas JP, Lanzino G, Huston J, et al. Nonstenotic carotid plaques and embolic stroke of undetermined source: a multimodality review. AJNR Am J Neuroradiol 2023;44:118-124.
crossref pmid
151. Kashiwazaki D, Koh M, Uchino H, Akioka N, Kuwayama N, Noguchi K, et al. Hypoxia accelerates intraplaque neovascularization derived from endothelial progenitor cells in carotid stenosis. J Neurosurg 2018;131:884-891.
crossref pmid
152. Goyal M, Singh N, Marko M, Hill MD, Menon BK, Demchuk A, et al. Embolic stroke of undetermined source and symptomatic nonstenotic carotid disease. Stroke 2020;51:1321-1325.
crossref pmid
153. Homma S, Messé SR, Rundek T, Sun YP, Franke J, Davidson K, et al. Patent foramen ovale. Nat Rev Dis Primers 2016;2:15086.
crossref pmid pdf
154. Yan C, Li H, Wang C, Yu H, Guo T, Wan L, et al. Frequency and size of in situ thrombus within patent foramen ovale. Stroke 2023;54:1205-1213.
crossref pmid
155. Bang OY, Chung JW, Lee MJ, Seo WK, Kim GM, Ahn MJ; OASIS-Cancer Study Investigators. Cancer-related stroke: an emerging subtype of ischemic stroke with unique pathomechanisms. J Stroke 2020;22:1-10.
crossref pmid pmc pdf
156. Navi BB, Kasner SE, Cushman M, Okwuosa TM, Fleming NH, Behr JM, et al. Classification and management of ischemic stroke in patients with active cancer: a scientific statement from the American Heart Association. Stroke 2026;57:e160-e173.
crossref pmid
157. Ahmed O, King NE, Qureshi MA, Choudhry AA, Osama M, Zehner C, et al. Non-bacterial thrombotic endocarditis: a clinical and pathophysiological reappraisal. Eur Heart J 2025;46:236-249.
crossref pmid pdf
158. Suomalainen OP, Martinez-Majander N, Broman J, Mannismäki L, Aro A, Curtze S, et al. Stroke in patients with atrial fibrillation: epidemiology, screening, and prognosis. J Clin Med 2023;13:30.
crossref pmid pmc
159. Jordan K, Yaghi S, Poppas A, Chang AD, Mac Grory B, Cutting S, et al. Left atrial volume index is associated with cardioembolic stroke and atrial fibrillation detection after embolic stroke of undetermined source. Stroke 2019;50:1997-2001.
pmid pmc
160. Chousou PA, Chattopadhyay R, Ring L, Khadjooi K, Warburton EA, Mukherjee T, et al. Atrial fibrillation in embolic stroke of undetermined source: role of advanced imaging of left atrial function. Eur J Prev Cardiol 2023;30:1965-1974.
crossref pmid pdf
161. Dhont S, Wouters F, Deferm S, Bekelaar K, Gruwez H, Meekers E, et al. Reduced left atrial appendage flow is associated with future atrial fibrillation after cryptogenic stroke. J Am Soc Echocardiogr 2023;36:824-831.
crossref pmid
162. Kamel H, Okin PM, Elkind MS, Iadecola C. Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke 2016;47:895-900.
crossref pmid pmc
163. Kühnlein P, Mahnkopf C, Majersik JJ, Wilson BD, Mitlacher M, Tirschwell D, et al. Atrial fibrosis in embolic stroke of undetermined source: a multicenter study. Eur J Neurol 2021;28:3634-3639.
crossref pmid pdf
164. Clark A, Ferkh A, Vandenberg J, Elhindi J, Thomas L. Altered left atrial metrics in patients with cryptogenic stroke: a systematic review and meta-analysis. Eur J Clin Invest 2024;54:e14175.
crossref pmid
165. Vad OB, van Vreeswijk N, Yassin AS, Blaauw Y, Paludan-Müller C, Kanters JK, et al. Atrial cardiomyopathy: markers and outcomes. Eur Heart J 2026;47:235-246.
crossref pmid pmc pdf
166. Kopczak A, Schindler A, Bayer-Karpinska A, Koch ML, Sepp D, Zeller J, et al. Complicated carotid artery plaques as a cause of cryptogenic stroke. J Am Coll Cardiol 2020;76:2212-2222.
crossref pmid
167. Coutinho JM, Derkatch S, Potvin AR, Tomlinson G, Kiehl TR, Silver FL, et al. Nonstenotic carotid plaque on CT angiography in patients with cryptogenic stroke. Neurology 2016;87:665-672.
crossref pmid pmc
168. Luo N, Shang ZY, Tao L, Yang BQ, Chen HS. Atherosclerosis as a potential cause of deep embolic stroke of undetermined source: a 3T high-resolution magnetic resonance imaging study. J Am Heart Assoc 2022;11:e026737.
crossref pmid pmc
169. Brunner G, Virani SS, Sun W, Liu L, Dodge RC, Nambi V, et al. Associations between carotid artery plaque burden, plaque characteristics, and cardiovascular events: the ARIC Carotid Magnetic Resonance Imaging Study. JAMA Cardiol 2021;6:79-86.
crossref pmid pmc
170. Kent DM, Wang AY. Patent foramen ovale and stroke: a review. JAMA 2025;334:1463-1473.
crossref pmid
171. Caso V, Turc G, Abdul-Rahim AH, Castro P, Hussain S, Lal A, et al. European Stroke Organisation (ESO) guidelines on the diagnosis and management of patent foramen ovale (PFO) after stroke. Eur Stroke J 2024;9:800-834.
crossref pmid pmc pdf
172. Pristipino C, Sievert H, D’Ascenzo F, Mas JL, Meier B, Scacciatella P, et al. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. EuroIntervention 2019;14:1389-1402.
crossref pmid
173. Kim BJ, Sohn H, Sun BJ, Song JK, Kang DW, Kim JS, et al. Imaging characteristics of ischemic strokes related to patent foramen ovale. Stroke 2013;44:3350-3356.
crossref pmid
174. He D, Li Q, Xu G, Hu Z, Li X, Guo Y, et al. Clinical and imaging characteristics of PFO-related stroke with different amounts of right-to-left shunt. Brain Behav 2018;8:e01122.
crossref pmid pmc pdf
175. Vidal-Calés P, Llull L, Lanthier S, Del Portillo JH, Desjardins L, Houde C, et al. Patent foramen ovale closure in older patients with cryptogenic stroke: current evidence and next steps. Struct Heart 2025;9:100699.
crossref pmid pmc
176. Paolucci M, Vincenzi C, Romoli M, Amico G, Ceccherini I, Lattanzi S, et al. The genetic landscape of patent foramen ovale: a systematic review. Genes (Basel) 2021;12:1953.
crossref pmid pmc
177. Nouh AM, Staff I, Finelli PF. Three territory sign: an MRI marker of malignancy-related ischemic stroke (Trousseau syndrome). Neurol Clin Pract 2019;9:124-128.
pmid pmc
178. Navi BB, Iadecola C. Ischemic stroke in cancer patients: a review of an underappreciated pathology. Ann Neurol 2018;83:873-883.
crossref pmid pmc pdf
TOOLS
Share :
Facebook Twitter Linked In Google+
Graph View
  • 0 Crossref
  •   Scopus
  • 1,381 View
  • 49 Download


ABOUT JoS
AUTHOR INFORMATION
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
Editorial Office
Department of Neurology, Asan Medical Center,Ulsan University College of Medicine
88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
Submission, status and progress, etc ⟫ E-mail: editor@j-stroke.org
Website and system ⟫ E-mail: support@m2-pi.com
Publishing company ⟫ E-mail: ka72sus@smileml.com
Developed in M2PI
Copyright © 2026 by Korean Stroke Society.
Close layer
prev next